
Krystyna Pawlak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8260626/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology, 2019, 100, 213-222.	1.3	295
2	Hyperfibrinolysis, uPA/suPAR System, Kynurenines, and the Prevalence of Cardiovascular Disease in Patients With Chronic Renal Failure on Conservative Treatment. American Journal of the Medical Sciences, 2010, 339, 5-9.	0.4	284
3	Kynurenine and its metabolites in Alzheimer's disease patients. Advances in Medical Sciences, 2010, 55, 204-211.	0.9	215
4	The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis, 2009, 204, 309-314.	0.4	107
5	Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values?. Kidney and Blood Pressure Research, 2007, 30, 408-415.	0.9	98
6	Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. American Journal of Hematology, 2006, 81, 832-837.	2.0	87
7	Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. International Urology and Nephrology, 2001, 33, 399-404.	0.6	80
8	Indoxyl sulfate – the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrology, 2017, 18, 35.	0.8	78
9	HEMOSTASIS, PLATELET FUNCTION AND SEROTONIN IN ACUTE AND CHRONIC RENAL FAILURE. Thrombosis Research, 1996, 83, 351-361.	0.8	76
10	Kynurenine pathway $\hat{a} \in \hat{a}$ a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Advances in Medical Sciences, 2010, 55, 196-203.	0.9	75
11	Kynurenine, quinolinic acid—The new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis, 2009, 204, 561-566.	0.4	73
12	THE COAGULO-LYTIC SYSTEM AND ENDOTHELIAL FUNCTION IN CYCLOSPORINE-TREATED KIDNEY ALLOGRAFT RECIPIENTS. Transplantation, 1996, 62, 828-830.	0.5	70
13	NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: Are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine?. International Journal of Cardiology, 2008, 127, 290-291.	0.8	67
14	Oxidative Stress – a Link between Endothelial Injury, Coagulation Activation, and Atherosclerosis in Haemodialysis Patients. American Journal of Nephrology, 2004, 24, 154-161.	1.4	66
15	Serum neutrophil gelatinaseâ€associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology, 2008, 13, 153-156.	0.7	63
16	Is Hepcidin a Link between Anemia, Inflammation and Liver Function in Hemodialyzed Patients?. American Journal of Nephrology, 2005, 25, 586-590.	1.4	56
17	Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis, 2007, 190, 199-204.	0.4	51
18	Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clinical Biochemistry, 2005, 38, 700-705.	0.8	50

#	Article	IF	CITATIONS
19	Apelin, a Novel Adipocytokine, in Relation to Endothelial Function and Inflammation in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3466-3469.	0.3	44
20	Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with preâ€dialysis blood pressure and the acute phase response. Nephrology Dialysis Transplantation, 2001, 16, 1442-1447.	0.4	42
21	Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thrombosis and Haemostasis, 2009, 102, 49-55.	1.8	41
22	Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clinical Biochemistry, 2011, 44, 838-843.	0.8	41
23	Indoxyl Sulfate Promotes Arterial Thrombosis in Rat Model via Increased Levels of Complex TF/VII, PAI-1, Platelet Activation as Well as Decreased Contents of SIRT1 and SIRT3. Frontiers in Physiology, 2018, 9, 1623.	1.3	37
24	Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clinical Biochemistry, 2007, 40, 81-85.	0.8	36
25	Oxidized LDL to autoantibodies against oxLDL ratio – The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis, 2012, 224, 252-257.	0.4	36
26	Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagulation and Fibrinolysis, 2009, 20, 590-594.	0.5	35
27	Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Advances in Medical Sciences, 2008, 53, 32-6.	0.9	34
28	Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine, 2008, 43, 98-101.	1.4	34
29	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 836.	1.3	34
30	Resistin, a New Adipokine, Is Related to Inflammation and Renal Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3434-3436.	0.3	33
31	Endocan — the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clinical Biochemistry, 2015, 48, 425-430.	0.8	33
32	Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thrombosis Research, 2009, 124, 452-457.	0.8	31
33	Kynurenine and Its Metabolites—Kynurenic Acid and Anthranilic Acid are Associated With Soluble Endothelial Adhesion Molecules and Oxidative Status in Patients With Chronic Kidney Disease. American Journal of the Medical Sciences, 2009, 338, 293-300.	0.4	31
34	Hepatitis intensified oxidative stress, MIP-1β and RANTES plasma levels in uraemic patients. Cytokine, 2004, 28, 197-204.	1.4	29
35	Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thrombosis Research, 2003, 109, 247-251.	0.8	27
36	Hepcidin, an Acute-Phase Protein and a Marker of Inflammation in Kidney Transplant Recipients With and Without Coronary Artery Disease. Transplantation Proceedings, 2006, 38, 2895-2898.	0.3	27

#	Article	IF	CITATIONS
37	Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. Molecular and Cellular Biochemistry, 2016, 421, 1-18.	1.4	27
38	The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thrombosis Research, 2008, 122, 328-335.	0.8	25
39	Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thrombosis Research, 2010, 125, e40-e45.	0.8	25
40	Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?. Translational Research, 2012, 160, 346-354.	2.2	25
41	Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio — Are they real oxidative stress markers in dialyzed patients?. Life Sciences, 2013, 92, 253-258.	2.0	25
42	The activation of the kynurenine pathway in a rat model with renovascular hypertension. Experimental Biology and Medicine, 2017, 242, 750-761.	1.1	25
43	Oxidative Stress Influences CC-Chemokine Levels in Hemodialyzed Patients. Nephron Physiology, 2004, 96, p105-p112.	1.5	24
44	Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thrombosis Research, 2006, 117, 517-522.	0.8	24
45	Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology, 2007, 12, 246-253.	0.7	23
46	The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. Bone, 2017, 105, 1-10.	1.4	23
47	The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite – 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease. PLoS ONE, 2016, 11, e0163526.	1.1	23
48	A possible role of thrombinâ€activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrology Dialysis Transplantation, 2001, 16, 1692-1696.	0.4	22
49	Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thrombosis Research, 2007, 120, 871-876.	0.8	22
50	Thyroid Function, Endothelium, and Inflammation in Hemodialyzed Patients: Possible Relations?. , 2007, 17, 30-37.		22
51	The Biomechanical Testing for the Assessment of Bone Quality in an Experimental Model of Chronic Kidney Disease. Nephron, 2016, 132, 51-58.	0.9	22
52	Importance of Serotonergic Mechanisms in the Thrombotic Complications in Hemodialyzed Patients Treated with Erythropoietin. Nephron, 2000, 84, 305-311.	0.9	21
53	Sulodexide induces hepatocyte growth factor release in humans. European Journal of Pharmacology, 2007, 558, 167-171.	1.7	20
54	Carotid atherosclerosis is associated with enhanced β-chemokine levels in patients on continuous ambulatory peritoneal dialysis. Atherosclerosis, 2006, 186, 146-151.	0.4	19

Krystyna Pawlak

#	Article	IF	CITATIONS
55	Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease. International Urology and Nephrology, 2018, 50, 127-135.	0.6	19
56	A Potent 5-Hydroxytryptamine Receptor (5-HT2A) Antagonist, DV-7028, Delays Arterial Thrombosis Development in Rats. Thrombosis Research, 1998, 90, 259-270.	0.8	18
57	Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 787-792.	0.4	18
58	Circulating β-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients – Role of oxidative stress. Cytokine, 2005, 31, 18-24.	1.4	18
59	Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thrombosis Research, 2007, 120, 797-803.	0.8	18
60	Systemic Levels of MMP2/TIMP2 and Cardiovascular Risk in CAPD Patients. Nephron Clinical Practice, 2010, 115, c251-c258.	2.3	18
61	Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 535-548.	2.5	18
62	PERIPHERAL SEROTONERGIC SYSTEM IN UREMIA. Thrombosis Research, 1996, 83, 189-194.	0.8	17
63	Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients. Thrombosis and Haemostasis, 2004, 92, 646-653.	1.8	17
64	3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1β (CCL4) in patients with chronic kidney disease. Clinical Biochemistry, 2010, 43, 1101-1106.	0.8	17
65	Immune suppression of IgG response against dairy proteins in major depression. BMC Psychiatry, 2017, 17, 268.	1.1	17
66	Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Thrombosis Research, 2008, 121, 543-548.	0.8	16
67	Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review. Advances in Medical Sciences, 2017, 62, 52-64.	0.9	16
68	Simultaneous use of erythropoietin and LFMâ€A13 as a new therapeutic approach for colorectal cancer. British Journal of Pharmacology, 2018, 175, 743-762.	2.7	16
69	Inflammation but not oxidative stress is associated with β-chemokine levels and prevalence of cardiovascular disease in uraemic patients. Cytokine, 2006, 35, 258-262.	1.4	15
70	Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thrombosis Research, 2007, 119, 475-480.	0.8	15
71	Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease—Apart or Together?. Nutrients, 2021, 13, 809.	1.7	15
72	Benzophenone-3, a chemical UV-filter in cosmetics: is it really safe for children and pregnant women?. Postepy Dermatologii I Alergologii, 2022, 39, 26-33.	0.4	15

Krystyna Pawlak

#	Article	IF	CITATIONS
73	Possible New Role of Monocyte Chemoattractant Protein-1 in Hemodialysis Patients with Cardiovascular Disease. American Journal of Nephrology, 2004, 24, 635-640.	1.4	14
74	Possible Relations Between Thyroid Function, Endothelium, and Kidney and Liver Function in Kidney Allograft Recipients. Transplantation Proceedings, 2006, 38, 3509-3513.	0.3	14
75	Antithrombotic Activity of Dermatan Sulphates, Heparins and their Combination in an Animal Model of Arterial Thrombosis. Thrombosis and Haemostasis, 1996, 76, 1102-1107.	1.8	14
76	Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. Medical Science Monitor, 2006, 12, CR181-5.	0.5	13
77	Inflammatory Markers and Platelet Aggregation Tests as Predictors of Hemoglobin and Endogenous Erythropoietin Levels in Hemodialysis Patients. Nephron, 2002, 91, 671-681.	0.9	12
78	Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients. American Journal of Nephrology, 2004, 24, 624-629.	1.4	12
79	Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 84-91.	0.7	12
80	Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis. Thrombosis Research, 2012, 129, 704-709.	0.8	12
81	RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. Cytokine, 2018, 106, 19-28.	1.4	12
82	Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. Journal of Nephrology, 2006, 19, 150-4.	0.9	12
83	RELATIONS BETWEEN OXIDATIVE STRESS, HEPATOCYTE GROWTH FACTOR, AND LIVER DISEASE IN HEMODIALYSIS PATIENTS. Renal Failure, 2002, 24, 825-837.	0.8	11
84	Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 245-250.	0.7	11
85	Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thrombosis Research, 2008, 123, 166-170.	0.8	11
86	IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncology Letters, 2011, 2, 1155-1159.	0.8	11
87	The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: The effect of dialysis treatment. Diabetes Research and Clinical Practice, 2012, 98, 264-270.	1.1	11
88	YKL-40 in hemodialyzed patients with and without cardiovascular complications – The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine, 2013, 62, 75-80.	1.4	11
89	Soluble angiogenesis markers in gastric tumor patients Folia Histochemica Et Cytobiologica, 2009, 47, 81-6.	0.6	11
90	Endothelial Function and Novel Adhesion Molecule CD44 in Kidney Allograft Recipients. Transplantation Proceedings, 2008, 40, 3470-3473.	0.3	10

#	Article	IF	CITATIONS
91	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. Bone, 2018, 113, 124-136.	1.4	10
92	Tissue factor pathway inhibitor release and depletion by sulodexide in humans. Advances in Medical Sciences, 2009, 54, 32-6.	0.9	10
93	Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. International Journal of Clinical and Laboratory Research, 1993, 23, 42-44.	1.0	9
94	Long-term Effects of Erythropoietin on Platelet Serotonin Storage and Platelet Aggregation in Hemodialysis Patients with Reference to Ketanserin Treatment. Thrombosis Research, 1998, 90, 171-180.	0.8	9
95	Long-Term Erythropoietin Therapy Decreases CC-Chemokine Levels and Intima-Media Thickness in Hemodialyzed Patients. American Journal of Nephrology, 2006, 26, 497-502.	1.4	9
96	Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-Â1 during haemodialysis: a cross-over study. Nephrology Dialysis Transplantation, 2007, 22, 1690-1696.	0.4	9
97	Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagulation and Fibrinolysis, 2007, 18, 467-471.	0.5	9
98	Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 338-345.	0.7	9
99	Hepcidin is Linked to Anemia and Inflammation in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 418-421.	1.1	9
100	MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. Cancers, 2021, 13, 3203.	1.7	9
101	Combined perioperative plasma endoglin and VECFa assessment in colorectal cancer patients Folia Histochemica Et Cytobiologica, 2009, 47, 231-6.	0.6	9
102	Anthranilic Acid–uraemic Toxin Damaged Red Cell's Membrane. International Urology and Nephrology, 2005, 37, 621-627.	0.6	8
103	Correlations Between Leptin, Body Composition, Bone Mineral Density, and Bone Metabolism in Kidney Transplant Recipients. Transplantation Proceedings, 2005, 37, 2151-2153.	0.3	8
104	Effect of Sulodexide on Plasma Transforming Growth Factor-β1 in Healthy Volunteers. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 60-65.	0.7	8
105	Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients Folia Histochemica Et Cytobiologica, 2009, 46, 487-92.	0.6	8
106	Effect of diabetes and oxidative stress on plasma CCL23 levels in patients with severe chronic kidney disease. Polish Archives of Internal Medicine, 2014, 124, 459-466.	0.3	8
107	Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. Journal of Nephrology, 2007, 20, 370-2.	0.9	8
108	Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. Clinical Transplantation, 2001, 15, 349-353.	0.8	7

#	Article	IF	CITATIONS
109	Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: A cross-over study. Thrombosis Research, 2009, 123, 631-636.	0.8	7
110	Relationships between Insulin-Like Growth Factor I and Selected Clinico-Morphological Parameters in Colorectal Cancer Patients. Polski Przeglad Chirurgiczny, 2011, 83, 250-7.	0.2	7
111	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. PeerJ, 2017, 5, e3199.	0.9	7
112	Ketanserin Lowers Erythropoietin Concentration in Hemodialyzed Patients Treated with the Hormone. Journal of Cardiovascular Pharmacology, 1995, 26, 621-626.	0.8	6
113	Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy. Nephrology Dialysis Transplantation, 1996, 11, 2444-2448.	0.4	6
114	Renal function, proteinuria and ACEâ€inhibitor therapy as determinants of plasma levels of endothelial markers. Nephrology Dialysis Transplantation, 2002, 17, 526-528.	0.4	6
115	Interleukin-21 in hemodialyzed patients: Association with the etiology of chronic kidney disease and the seropositivity against hepatitis C virus infection. Clinical Biochemistry, 2011, 44, 1416-1420.	0.8	6
116	The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease. International Urology and Nephrology, 2019, 51, 491-502.	0.6	6
117	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. International Journal of Molecular Sciences, 2020, 21, 5979.	1.8	6
118	Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics, 2021, 13, 1222.	2.0	6
119	Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells. Current Pharmaceutical Biotechnology, 2017, 18, 127-137.	0.9	6
120	Tissue factor and its inhibitor in human non-crescentic glomerulonephritisimmunostaining vs plasma and urinary levels. Nephrology Dialysis Transplantation, 2006, 21, 3450-3457.	0.4	5
121	Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxidative Stress and Inflammation in Hemodialyzed Patients. American Journal of Nephrology, 2007, 27, 221-225.	1.4	5
122	Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients. Clinical Biochemistry, 2010, 43, 1393-1398.	0.8	5
123	Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas – the new putative determinants of endothelial dysfunction in haemodialysis patients. Thrombosis Research, 2010, 126, 393-398.	0.8	5
124	Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 1262.	1.8	5
125	Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study. Cytokine, 2007, 40, 98-104.	1.4	4
126	Markers of Bone Metabolism in Hemodialyses and Hemodiafiltration. Renal Failure, 2007, 29, 595-601.	0.8	4

#	Article	IF	CITATIONS
127	Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165528.	1.8	4
128	The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1697-1711.	2.5	4
129	Indoleamine 2,3 Dioxygenase 1—The Potential Link between the Innate Immunity and the Ischemia-Reperfusion-Induced Acute Kidney Injury?. International Journal of Molecular Sciences, 2022, 23, 6176.	1.8	4
130	Ketanserin and Erythropoiesis in Hemodialysis Patients with Polycystic Kidneys. American Journal of Nephrology, 1996, 16, 451-452.	1.4	3
131	Erythropoietin and uremic platelet aggregation in vivo and in vitro. International Journal of Clinical and Laboratory Research, 1996, 26, 199-202.	1.0	3
132	Erythropoietin Therapy Decreased Tissue Factor, Its Pathway Inhibitor, and Oxidative Stress in Peritoneal Dialysis Patients with Diabetes. Nephron Clinical Practice, 2007, 107, c20-c25.	2.3	3
133	Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer – evaluation of the prognostic significance of these agents. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1439-45.	1.4	3
134	oxLDL – the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients. Thrombosis Research, 2014, 134, 711-716.	0.8	3
135	The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats. Expert Opinion on Therapeutic Targets, 2019, 23, 353-364.	1.5	3
136	P0690CORRELATIONS BETWEEN OPG/RANKL/RANK AXIS, VITAMIN D STATUS, PTH AND VASCULAR CALCIFICATION IN AN ADENINE-INDUCED MODEL OF CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	3
137	Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling. International Journal of Molecular Sciences, 2021, 22, 6563.	1.8	3
138	Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin. Thrombosis Research, 1995, 78, 541-546.	0.8	2
139	Chronic viral hepatitis and iron affect the plasma levels of LIGHT—a new member of the TNF superfamily in uraemic haemodialyzed patients. Cytokine, 2007, 39, 201-206.	1.4	2
140	Prohepcidin in pregnancy: Acute phase protein, marker of iron metabolism, or both?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 293-294.	0.5	2
141	Serum PTH, PTH1R/ATF4 pathway, and the sRANKL/OPG system in bone as a new link between bone growth, cross-sectional geometry, and strength in young rats with experimental chronic kidney disease. Cytokine, 2021, 148, 155685.	1.4	2
142	Comparison of Different Assays for von Willebrand Factor in Hemodialysis Patients. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 308-315.	0.5	1
143	TGF-β1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 493-494.	0.7	1
144	Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. Thrombosis Research, 2008, 121, 787-791.	0.8	1

#	Article	IF	CITATIONS
145	LIGHT—A new member of the TNF superfamily in the plasma, dialysate and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis. Clinical Biochemistry, 2007, 40, 1240-1244.	0.8	0
146	FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
147	P0871THE IMPACT OF ENDOGENOUS PTH/PTH1R/ATF4 AXIS ON TRABECULAR AND CORTICAL BONE REMODELING AND BONE GROWTH OF YOUNG RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
148	P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
149	P0874THE IMPACT OF CHRONIC EXPOSURE TO INDOXYL SULFATE ON BONE TURNOVER MARKERS, PTH, VITAMIN D3, AND BIOMECHANICAL AND DENSITOMETRIC PROPERTIES OF BONES IN RAT MODEL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
150	MO564CHRONIC EXPOSURE TO INDOXYL SULFATE CHANGES BONE PROPERTIES AND EXPRESSION OF SIRT2, SIRT3, AND SIRT7 GENES*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0